New hope for hard-to-treat pancreatic cancer: targeted drug enters phase 2 trial
NCT ID NCT07589569
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tests an experimental drug called HRS-7058 in people with advanced pancreatic cancer that has a specific change in the KRAS gene (G12C mutation). Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors and how safe it is. About 92 adults aged 18 to 75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210003, China
Contact
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
Contact
Conditions
Explore the condition pages connected to this study.